BR9306226A - Composiçao de cura de feridas e tratamento de distúrbios fibróticos e método para a sua preparaçao - Google Patents
Composiçao de cura de feridas e tratamento de distúrbios fibróticos e método para a sua preparaçaoInfo
- Publication number
- BR9306226A BR9306226A BR9306226A BR9306226A BR9306226A BR 9306226 A BR9306226 A BR 9306226A BR 9306226 A BR9306226 A BR 9306226A BR 9306226 A BR9306226 A BR 9306226A BR 9306226 A BR9306226 A BR 9306226A
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- preparation
- treatment
- wound healing
- fibrotic disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929206861A GB9206861D0 (en) | 1992-03-28 | 1992-03-28 | Wound healing and treatment of fibrotic disorders |
PCT/GB1993/000586 WO1993019769A1 (en) | 1992-03-28 | 1993-03-22 | Wound healing and treatment of fibrotic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9306226A true BR9306226A (pt) | 1996-12-03 |
Family
ID=10713078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9306226A BR9306226A (pt) | 1992-03-28 | 1993-03-22 | Composiçao de cura de feridas e tratamento de distúrbios fibróticos e método para a sua preparaçao |
Country Status (19)
Country | Link |
---|---|
US (1) | US6331298B1 (pt) |
EP (1) | EP0646012B1 (pt) |
JP (2) | JP3919212B2 (pt) |
AT (1) | ATE230605T1 (pt) |
AU (1) | AU673161B2 (pt) |
BR (1) | BR9306226A (pt) |
CA (1) | CA2131383C (pt) |
CZ (1) | CZ236694A3 (pt) |
DE (1) | DE69332624T2 (pt) |
DK (1) | DK0646012T3 (pt) |
ES (1) | ES2189790T3 (pt) |
GB (1) | GB9206861D0 (pt) |
HU (1) | HUT68905A (pt) |
NO (1) | NO943466D0 (pt) |
NZ (1) | NZ249937A (pt) |
PT (1) | PT646012E (pt) |
RU (1) | RU94042387A (pt) |
SK (1) | SK116894A3 (pt) |
WO (1) | WO1993019769A1 (pt) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
US7384634B2 (en) * | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
US5449671A (en) * | 1993-09-29 | 1995-09-12 | Alcon Laboratories, Inc. | Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery |
US5411940A (en) * | 1993-09-29 | 1995-05-02 | Alcon Laboratories, Inc. | Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma |
WO1995009004A1 (en) * | 1993-09-29 | 1995-04-06 | Alcon Laboratories, Inc. | Compositions containing growth factors and antiplastic agents |
WO1995026203A1 (en) * | 1994-03-29 | 1995-10-05 | The Victoria University Of Manchester | Wound healing |
GB2288118A (en) * | 1994-03-29 | 1995-10-11 | Univ Manchester | Wound healing composition |
US5621093A (en) * | 1995-06-06 | 1997-04-15 | Anika Research, Inc. | Steam-sterilizing solid hyaluronic acid |
GB2304045A (en) * | 1995-08-04 | 1997-03-12 | Univ Manchester | Betaglycan compositions for promoting the healing of wounds and fibrotic diseases |
GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
EP0941108B1 (en) * | 1996-12-04 | 2002-10-16 | Renovo Limited | Wound healing and treatment of fibrosis |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
AU2006202209B2 (en) | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
CA2613889A1 (en) * | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
GB0514262D0 (en) * | 2005-07-12 | 2005-08-17 | Renovo Ltd | Promotion of epithelial regeneration |
US20070122448A1 (en) * | 2005-11-28 | 2007-05-31 | Alireza Rezania | Compositions and methods to create a vascularized environment for cellular transplantation |
GB0604938D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Proteins, nucleic acids and medicaments |
GB0604966D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Medicaments and proteins |
GB0604964D0 (en) * | 2006-03-11 | 2006-04-19 | Renovo Ltd | Protein folding |
WO2007127927A2 (en) | 2006-04-28 | 2007-11-08 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
GB0617816D0 (en) * | 2006-09-11 | 2006-10-18 | Renovo Ltd | Nucleic acids and methods of protein expression |
KR20150072458A (ko) | 2006-11-15 | 2015-06-29 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
WO2008094597A2 (en) * | 2007-01-30 | 2008-08-07 | University Of Georgia Research Foundation, Inc. | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc) |
CN104250632B (zh) | 2007-07-01 | 2018-09-11 | 生命扫描有限公司 | 单个多能干细胞培养 |
US9080145B2 (en) * | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
US8492329B2 (en) * | 2007-07-12 | 2013-07-23 | Compugen Ltd. | Bioactive peptides and methods of using same |
MX2010000746A (es) | 2007-07-18 | 2010-07-05 | Lifescan Inc | Diferenciacion de celulas madre embrionarias humanas. |
KR101617243B1 (ko) | 2007-07-31 | 2016-05-02 | 라이프스캔, 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
KR101592182B1 (ko) * | 2007-11-27 | 2016-02-05 | 라이프스캔, 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
JP2011507599A (ja) | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 改良医療デバイス |
US20110217313A1 (en) * | 2007-12-21 | 2011-09-08 | Becker David L | Treatment of orthopedic conditions |
WO2009085277A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of abnormal or excessive scars |
KR101731474B1 (ko) | 2008-02-21 | 2017-05-11 | 얀센 바이오테크 인코포레이티드 | 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물 |
US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
PL2942392T3 (pl) | 2008-06-30 | 2019-02-28 | Janssen Biotech, Inc | Różnicowanie pluripotencjalnych komórek macierzystych |
WO2010003935A2 (en) * | 2008-07-07 | 2010-01-14 | Laboratoire Medidom S.A. | Temperature reducing, healing wound dressing |
US20110305672A1 (en) | 2008-07-25 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME |
EP2318520B1 (en) | 2008-07-25 | 2017-10-11 | The University Of Georgia Research Foundation, Inc. | Compositions for mesoderm derived isl1+ multipotent cells (imps), epicardial progenitor cells (epcs) and multipotent cxcr4+cd56+ cells (c56cs) and methods of use |
US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
CN102333862B (zh) | 2008-10-31 | 2018-04-27 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌谱系的分化 |
US9234178B2 (en) | 2008-10-31 | 2016-01-12 | Janssen Biotech, Inc. | Differentiation of human pluripotent stem cells |
JP5719305B2 (ja) * | 2008-11-20 | 2015-05-13 | ヤンセン バイオテツク,インコーポレーテツド | 平面支持体上での細胞付着及び培養のための方法及び組成物 |
AU2009316580B2 (en) | 2008-11-20 | 2016-04-14 | Janssen Biotech, Inc. | Pluripotent stem cell culture on micro-carriers |
RU2540016C2 (ru) | 2009-07-20 | 2015-01-27 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека |
MX340952B (es) * | 2009-07-20 | 2016-07-29 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas. |
WO2011011300A2 (en) | 2009-07-20 | 2011-01-27 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
AU2010319921A1 (en) * | 2009-10-29 | 2012-05-17 | Janssen Biotech Inc. | Pluripotent stem cells |
DE202009017772U1 (de) * | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
SG181685A1 (en) | 2009-12-23 | 2012-07-30 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells |
US9150833B2 (en) | 2009-12-23 | 2015-10-06 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
RU2607380C2 (ru) * | 2010-03-01 | 2017-01-10 | Янссен Байотек, Инк. | Способы очистки клеток, производных от плюрипотентных стволовых клеток |
WO2011143299A2 (en) | 2010-05-12 | 2011-11-17 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
SG187603A1 (en) | 2010-08-12 | 2013-03-28 | Janssen Biotech Inc | Treatment of diabetes with pancreatic endocrine precursor cells |
MX348537B (es) | 2010-08-31 | 2017-06-07 | Janssen Biotech Inc | Diferencia de celulas madre pluripotentes. |
US9506036B2 (en) | 2010-08-31 | 2016-11-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
EP3211070A1 (en) | 2010-08-31 | 2017-08-30 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
EP2652125B1 (en) | 2010-12-15 | 2017-04-26 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
RU2705001C2 (ru) | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки |
CN104160018A (zh) | 2012-03-07 | 2014-11-19 | 詹森生物科技公司 | 用于扩增和维持多能干细胞的成分确定的培养基 |
ES2690118T3 (es) | 2012-06-08 | 2018-11-19 | Janssen Biotech, Inc. | Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
CA2896750A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
BR112015015770A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas |
KR101942769B1 (ko) | 2012-12-31 | 2019-01-28 | 얀센 바이오테크 인코포레이티드 | Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화 |
PT2972193T (pt) | 2013-03-13 | 2020-04-23 | Univ Miami | Método para isolamento e purificação de microvesículas de sobrenadantes de cultura celular e fluidos biológicos |
WO2015175307A1 (en) | 2014-05-16 | 2015-11-19 | Janssen Biotech, Inc. | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
US10465188B2 (en) | 2014-08-22 | 2019-11-05 | Auckland Uniservices Limited | Channel modulators |
WO2017094001A1 (en) | 2015-11-30 | 2017-06-08 | Kadimastem Ltd | Methods for differentiating and purifying pancreatic endocrine cells |
CA3012294A1 (en) * | 2016-02-17 | 2017-08-24 | Novartis Ag | Tgfbeta 2 antibodies |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
JP7531887B2 (ja) | 2020-07-31 | 2024-08-13 | 学校法人関西医科大学 | TGF-βを含む組織の線維化抑制剤 |
MX2023001927A (es) | 2020-08-21 | 2023-03-09 | Univ Miami | Composiciones y metodos de tratamiento usando microvesiculas de celulas madre mesenquimaticas derivadas de medula osea. |
WO2023205158A1 (en) | 2022-04-19 | 2023-10-26 | University Of Miami | Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155214A (en) * | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
GB8823649D0 (en) * | 1988-10-07 | 1988-11-16 | Geistlich Soehne Ag | Chemical compounds |
IE61346B1 (en) | 1988-11-02 | 1994-11-02 | Genentech Inc | A permeable material to fit around the teeth or gums of a mammal |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
WO1991010727A1 (en) | 1990-01-22 | 1991-07-25 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors |
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
-
1992
- 1992-03-28 GB GB929206861A patent/GB9206861D0/en active Pending
-
1993
- 1993-03-22 EP EP93906723A patent/EP0646012B1/en not_active Expired - Lifetime
- 1993-03-22 CZ CZ942366A patent/CZ236694A3/cs unknown
- 1993-03-22 JP JP51719393A patent/JP3919212B2/ja not_active Expired - Fee Related
- 1993-03-22 BR BR9306226A patent/BR9306226A/pt not_active Application Discontinuation
- 1993-03-22 ES ES93906723T patent/ES2189790T3/es not_active Expired - Lifetime
- 1993-03-22 PT PT93906723T patent/PT646012E/pt unknown
- 1993-03-22 SK SK1168-94A patent/SK116894A3/sk unknown
- 1993-03-22 AT AT93906723T patent/ATE230605T1/de not_active IP Right Cessation
- 1993-03-22 DE DE69332624T patent/DE69332624T2/de not_active Expired - Lifetime
- 1993-03-22 DK DK93906723T patent/DK0646012T3/da active
- 1993-03-22 NZ NZ249937A patent/NZ249937A/en not_active IP Right Cessation
- 1993-03-22 HU HU9402771A patent/HUT68905A/hu unknown
- 1993-03-22 RU RU94042387/14A patent/RU94042387A/ru unknown
- 1993-03-22 AU AU37623/93A patent/AU673161B2/en not_active Ceased
- 1993-03-22 CA CA002131383A patent/CA2131383C/en not_active Expired - Lifetime
- 1993-03-22 WO PCT/GB1993/000586 patent/WO1993019769A1/en active IP Right Grant
- 1993-03-22 US US08/307,640 patent/US6331298B1/en not_active Expired - Fee Related
-
1994
- 1994-09-16 NO NO943466A patent/NO943466D0/no unknown
-
2005
- 2005-05-11 JP JP2005138819A patent/JP2005290009A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU673161B2 (en) | 1996-10-31 |
CA2131383A1 (en) | 1993-10-14 |
CZ236694A3 (en) | 1995-04-12 |
PT646012E (pt) | 2003-03-31 |
EP0646012B1 (en) | 2003-01-08 |
RU94042387A (ru) | 1996-11-10 |
EP0646012A1 (en) | 1995-04-05 |
HU9402771D0 (en) | 1995-01-30 |
CA2131383C (en) | 2002-07-16 |
JP3919212B2 (ja) | 2007-05-23 |
DK0646012T3 (da) | 2003-03-03 |
HUT68905A (en) | 1995-08-28 |
DE69332624D1 (de) | 2003-02-13 |
US6331298B1 (en) | 2001-12-18 |
GB9206861D0 (en) | 1992-05-13 |
DE69332624T2 (de) | 2003-10-02 |
NO943466L (no) | 1994-09-16 |
ES2189790T3 (es) | 2003-07-16 |
AU3762393A (en) | 1993-11-08 |
NO943466D0 (no) | 1994-09-16 |
SK116894A3 (en) | 1995-02-08 |
NZ249937A (en) | 1996-09-25 |
WO1993019769A1 (en) | 1993-10-14 |
ATE230605T1 (de) | 2003-01-15 |
JPH07505378A (ja) | 1995-06-15 |
JP2005290009A (ja) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9306226A (pt) | Composiçao de cura de feridas e tratamento de distúrbios fibróticos e método para a sua preparaçao | |
DE69331605D1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
EP1555025A3 (en) | Use of dehydroepiandrosterone analogs for the treatment of asthma | |
TR199801180T2 (xx) | Aneljestik etkiye sahip yeni bile�ikler. | |
IL128416A0 (en) | Pharmaceutical composition for the treatment of alzheimer's disease | |
DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
PL323798A1 (en) | Application of derivatives of vitamin d4 in treating skin diseases | |
DE69424777D1 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
ATE137965T1 (de) | Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege | |
DE69617729D1 (de) | Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom | |
ATE196738T1 (de) | Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände | |
ATE225177T1 (de) | Verwendung von (+)mefloquine zur behandlung von malaria | |
AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
ES2159294T3 (es) | Metodo y composicion para el tratamiento de la caida del cabello. | |
NO179245C (no) | Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet | |
NZ307601A (en) | Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions | |
NO960347L (no) | Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF | |
AU2269392A (en) | Method for treating immunological disorders and diseases | |
BR9713828A (pt) | Tratamento de tumores altamente vasculares | |
YU15301A (sh) | PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA | |
BR9609868A (pt) | Conjugado sintético de uma proteína e uma pluralidade de epítopos para uso em medicina processos para evitar a rejeição de um xenoenxerto ou pelo menos reduzir a extensão ou taxa de rejeição para tratar uma doença e sangue removido de um doador de sangue aparelho sangue composição farmaceuticamente aceitável e uso de um conjugado | |
CA2219978A1 (en) | Method for inhibiting neoplastic disease in mammals | |
BR9205031A (pt) | Derivados de indol,processo para sua preparacao,medicamento,uso e metodo para o tratamento ou a profilaxia de disturbios cognitivos | |
KR930700109A (ko) | 신경 질환 치료용 4,4'-[9h-플루오렌-9-일리덴비스(메틸렌)]-비스피리미딘 | |
IT8919216A0 (it) | Dispositivo per la cura chirurgica dell'astigmatismo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EH | Examination suspended | ||
EG | Technical examination (opinion): publication of technical examination (opinion) | ||
FC | Decision: refusal |